Dahlene N Fusco
Affiliation: Massachusetts General Hospital
- Non-oral treatment with ivermectin for disseminated strongyloidiasisDahlene N Fusco
Division of Infectious Diseases, and Department of Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, USA
Am J Trop Med Hyg 83:879-83. 2010..Obtaining subcutaneous ivermectin and dosing it appropriately is a challenge. These cases underscore the need for improved access to subcutaneous ivermectin and more pharmacological data to guide use of this treatment approach...
- Novel therapies for hepatitis C: insights from the structure of the virusDahlene N Fusco
Gastroenterology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Annu Rev Med 63:373-87. 2012..This review provides a guide to HCV drugs in various stages of development, including an introduction to their mechanism of action, state of clinical development, efficacy, and side effects...
- SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replicationRun Xuan Shao
MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Antiviral Res 97:101-7. 2013..Knockdown of SOCS1 alone with specific shRNA enhanced the antiviral effect of IFN compared with negative control. Thus, SOCS1 acts as a suppressor of type I IFN function against HCV...
- A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virusHong Zhao
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
J Hepatol 56:326-33. 2012..The precise mechanisms by which IFN exerts its antiviral effect against HCV have not yet been elucidated. We sought to identify host genes that mediate the antiviral effect of IFN-α by conducting a whole-genome siRNA library screen...
- A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replicationDahlene N Fusco
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Gastroenterology 144:1438-49, 1449.e1-9. 2013..In contrast to candidate approaches based on analyses of messenger RNA (mRNA) expression, identification of IEGs requires a broad functional approach...
- Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signalingKattareeya Kumthip
Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Virol 86:8581-91. 2012..We propose a model in which the binding of the C-terminal region of NS5A to STAT1 leads to decreased levels of P-STAT1, ISRE signaling, and ISG transcription and, ultimately, to preferential GT1 resistance to IFN treatment...
- IL28B inhibits hepatitis C virus replication through the JAK-STAT pathwayLeiliang Zhang
Gastrointestinal Unit, Department of Medicine, Warren 1007, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Hepatol 55:289-98. 2011..We sought to determine whether IL28B was capable of inhibiting HCV replication and to determine the pathway by which IL28B exhibits anti-HCV activity...
- Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfectionXinyan Liu
Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 8:e57483. 2013..Linezolid has immunomodulatory properties. We report on the effects of the three antibiotics on microbial clearance, pulmonary cytokines and clinical course in a murine model of influenza and MRSA coinfection...